| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Remodeling | 29 | 2015 | 318 | 2.860 |
Why?
|
| Myocardial Infarction | 23 | 2015 | 807 | 2.660 |
Why?
|
| Matrix Metalloproteinases | 16 | 2016 | 223 | 1.930 |
Why?
|
| Ventricular Function, Left | 19 | 2016 | 481 | 1.580 |
Why?
|
| Myocardium | 26 | 2018 | 1204 | 1.570 |
Why?
|
| Matrix Metalloproteinase 9 | 12 | 2016 | 160 | 1.500 |
Why?
|
| Matrix Metalloproteinase 2 | 13 | 2016 | 145 | 1.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 10 | 2014 | 85 | 1.160 |
Why?
|
| Atrial Fibrillation | 3 | 2016 | 248 | 1.030 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2017 | 106 | 1.000 |
Why?
|
| Myocardial Contraction | 11 | 2012 | 383 | 0.990 |
Why?
|
| Aortic Aneurysm, Thoracic | 10 | 2022 | 134 | 0.990 |
Why?
|
| Matrix Metalloproteinase 14 | 11 | 2016 | 44 | 0.950 |
Why?
|
| Swine | 26 | 2022 | 672 | 0.900 |
Why?
|
| Animals | 72 | 2022 | 20880 | 0.880 |
Why?
|
| Aorta, Thoracic | 9 | 2019 | 211 | 0.860 |
Why?
|
| Spinal Cord Ischemia | 2 | 2022 | 21 | 0.730 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 5 | 2010 | 59 | 0.720 |
Why?
|
| Myocytes, Cardiac | 9 | 2021 | 442 | 0.710 |
Why?
|
| Heart Transplantation | 1 | 2022 | 328 | 0.650 |
Why?
|
| Heart Arrest, Induced | 4 | 2006 | 52 | 0.640 |
Why?
|
| Disease Models, Animal | 27 | 2019 | 2550 | 0.640 |
Why?
|
| Myocardial Reperfusion Injury | 6 | 2012 | 84 | 0.610 |
Why?
|
| Promoter Regions, Genetic | 7 | 2012 | 614 | 0.600 |
Why?
|
| Transcription, Genetic | 3 | 2010 | 562 | 0.570 |
Why?
|
| Heart Diseases | 2 | 2021 | 276 | 0.550 |
Why?
|
| Cyclosporine | 2 | 2014 | 121 | 0.550 |
Why?
|
| Mice | 32 | 2021 | 8474 | 0.550 |
Why?
|
| Cardiomyopathies | 1 | 2017 | 167 | 0.540 |
Why?
|
| Recurrence | 2 | 2016 | 948 | 0.530 |
Why?
|
| Pulmonary Artery | 4 | 2014 | 323 | 0.530 |
Why?
|
| Ischemic Preconditioning | 1 | 2015 | 31 | 0.520 |
Why?
|
| Hindlimb | 1 | 2015 | 38 | 0.520 |
Why?
|
| Spinal Cord | 1 | 2015 | 244 | 0.480 |
Why?
|
| Heart | 5 | 2018 | 850 | 0.480 |
Why?
|
| Arteriovenous Fistula | 1 | 2014 | 25 | 0.470 |
Why?
|
| Pulmonary Veins | 1 | 2014 | 56 | 0.460 |
Why?
|
| Cilia | 3 | 2019 | 94 | 0.460 |
Why?
|
| Aortic Diseases | 4 | 2022 | 113 | 0.450 |
Why?
|
| Caspase Inhibitors | 4 | 2010 | 36 | 0.450 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 5 | 2006 | 59 | 0.440 |
Why?
|
| Cytokines | 5 | 2014 | 866 | 0.440 |
Why?
|
| Heart Ventricles | 8 | 2017 | 738 | 0.440 |
Why?
|
| Heart Conduction System | 2 | 2012 | 119 | 0.440 |
Why?
|
| Heart Failure | 7 | 2016 | 1179 | 0.430 |
Why?
|
| Fontan Procedure | 1 | 2014 | 129 | 0.420 |
Why?
|
| Electric Countershock | 1 | 2013 | 130 | 0.410 |
Why?
|
| Models, Cardiovascular | 2 | 2010 | 133 | 0.410 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2016 | 277 | 0.410 |
Why?
|
| Internship and Residency | 3 | 2022 | 596 | 0.390 |
Why?
|
| Enzyme Activation | 6 | 2016 | 791 | 0.380 |
Why?
|
| Time Factors | 18 | 2020 | 4655 | 0.380 |
Why?
|
| Animals, Newborn | 2 | 2016 | 396 | 0.380 |
Why?
|
| Hemodynamics | 13 | 2012 | 705 | 0.370 |
Why?
|
| Endotoxins | 1 | 2010 | 76 | 0.370 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2010 | 40 | 0.370 |
Why?
|
| Catheter Ablation | 3 | 2016 | 229 | 0.360 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2018 | 140 | 0.360 |
Why?
|
| Vascular Remodeling | 3 | 2021 | 34 | 0.360 |
Why?
|
| Finite Element Analysis | 1 | 2010 | 55 | 0.350 |
Why?
|
| Ventricular Pressure | 6 | 2014 | 82 | 0.340 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2010 | 239 | 0.330 |
Why?
|
| Leadership | 2 | 2021 | 136 | 0.330 |
Why?
|
| Enzyme Inhibitors | 5 | 2005 | 659 | 0.320 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 147 | 0.320 |
Why?
|
| Protein Kinase C | 2 | 2006 | 270 | 0.320 |
Why?
|
| Endothelin-1 | 2 | 2006 | 122 | 0.310 |
Why?
|
| Echocardiography | 9 | 2014 | 515 | 0.310 |
Why?
|
| Fibroblasts | 8 | 2019 | 902 | 0.300 |
Why?
|
| Humans | 38 | 2022 | 68549 | 0.300 |
Why?
|
| Cardiopulmonary Bypass | 4 | 2015 | 250 | 0.300 |
Why?
|
| Heart Valve Diseases | 2 | 2019 | 123 | 0.300 |
Why?
|
| Mice, Transgenic | 10 | 2014 | 1033 | 0.290 |
Why?
|
| Heart-Assist Devices | 1 | 2010 | 221 | 0.280 |
Why?
|
| Endovascular Procedures | 2 | 2022 | 366 | 0.280 |
Why?
|
| Aorta, Abdominal | 2 | 2017 | 97 | 0.280 |
Why?
|
| Heart Atria | 3 | 2014 | 206 | 0.280 |
Why?
|
| Oligopeptides | 3 | 2010 | 152 | 0.280 |
Why?
|
| Aortic Valve | 2 | 2019 | 249 | 0.280 |
Why?
|
| Fibrinolysin | 3 | 2011 | 33 | 0.280 |
Why?
|
| Biocompatible Materials | 1 | 2008 | 247 | 0.280 |
Why?
|
| Angiotensin II | 5 | 2018 | 220 | 0.270 |
Why?
|
| Computer Simulation | 1 | 2010 | 706 | 0.270 |
Why?
|
| Temperature | 2 | 2006 | 340 | 0.270 |
Why?
|
| MicroRNAs | 3 | 2019 | 447 | 0.270 |
Why?
|
| Enzyme Induction | 5 | 2012 | 118 | 0.270 |
Why?
|
| Aprotinin | 3 | 2011 | 55 | 0.270 |
Why?
|
| Hydroxamic Acids | 2 | 2003 | 84 | 0.260 |
Why?
|
| Fibrosis | 8 | 2018 | 371 | 0.260 |
Why?
|
| Antifibrinolytic Agents | 3 | 2010 | 52 | 0.260 |
Why?
|
| Gene Expression Regulation, Enzymologic | 7 | 2016 | 282 | 0.260 |
Why?
|
| Heart Injuries | 1 | 2005 | 25 | 0.260 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2005 | 22 | 0.260 |
Why?
|
| Random Allocation | 7 | 2010 | 442 | 0.250 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 2791 | 0.240 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2004 | 24 | 0.240 |
Why?
|
| Muscle Cells | 1 | 2004 | 30 | 0.240 |
Why?
|
| Mutation | 2 | 2021 | 1213 | 0.230 |
Why?
|
| Aortic Valve Stenosis | 2 | 2019 | 177 | 0.230 |
Why?
|
| Collagen | 9 | 2015 | 636 | 0.230 |
Why?
|
| Peptide Fragments | 2 | 2018 | 483 | 0.230 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2003 | 22 | 0.230 |
Why?
|
| General Surgery | 2 | 2021 | 95 | 0.230 |
Why?
|
| Male | 33 | 2022 | 37283 | 0.230 |
Why?
|
| Peptides | 2 | 2006 | 455 | 0.230 |
Why?
|
| Stroke Volume | 5 | 2014 | 586 | 0.220 |
Why?
|
| Female | 27 | 2022 | 38021 | 0.220 |
Why?
|
| Microdialysis | 7 | 2012 | 147 | 0.220 |
Why?
|
| Electrocardiography | 4 | 2014 | 601 | 0.220 |
Why?
|
| Basigin | 2 | 2016 | 53 | 0.210 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2002 | 153 | 0.210 |
Why?
|
| Blood Pressure | 6 | 2016 | 1449 | 0.210 |
Why?
|
| Vasoconstriction | 2 | 2015 | 81 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1293 | 0.200 |
Why?
|
| Transplantation, Heterologous | 1 | 2022 | 122 | 0.200 |
Why?
|
| Clinical Clerkship | 1 | 2022 | 63 | 0.200 |
Why?
|
| Kidney | 5 | 2018 | 945 | 0.200 |
Why?
|
| Ethics, Medical | 1 | 2022 | 86 | 0.200 |
Why?
|
| Pandemics | 2 | 2022 | 349 | 0.190 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2021 | 32 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2022 | 294 | 0.190 |
Why?
|
| Isoenzymes | 4 | 2006 | 308 | 0.190 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2021 | 61 | 0.190 |
Why?
|
| Pancreatectomy | 1 | 2022 | 129 | 0.190 |
Why?
|
| Aging | 3 | 2015 | 911 | 0.190 |
Why?
|
| Surgical Procedures, Operative | 1 | 2021 | 124 | 0.190 |
Why?
|
| Burns | 1 | 2022 | 83 | 0.190 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 1174 | 0.190 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 123 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 127 | 0.180 |
Why?
|
| Serine Proteinase Inhibitors | 2 | 2011 | 48 | 0.180 |
Why?
|
| Cells, Cultured | 6 | 2019 | 2673 | 0.180 |
Why?
|
| Needs Assessment | 1 | 2021 | 186 | 0.180 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2022 | 186 | 0.180 |
Why?
|
| Muscle Contraction | 1 | 2021 | 210 | 0.180 |
Why?
|
| Workplace | 1 | 2020 | 75 | 0.180 |
Why?
|
| Students, Medical | 1 | 2022 | 210 | 0.180 |
Why?
|
| beta-Galactosidase | 3 | 2010 | 88 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 212 | 0.180 |
Why?
|
| Tranexamic Acid | 2 | 2010 | 37 | 0.180 |
Why?
|
| Pancreatitis | 1 | 2022 | 279 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2020 | 64 | 0.170 |
Why?
|
| Catheterization, Peripheral | 1 | 2020 | 38 | 0.170 |
Why?
|
| Femoral Artery | 1 | 2020 | 139 | 0.170 |
Why?
|
| Heart Rate | 3 | 2010 | 568 | 0.170 |
Why?
|
| Mitral Valve Prolapse | 1 | 2019 | 40 | 0.170 |
Why?
|
| Exome | 1 | 2019 | 20 | 0.170 |
Why?
|
| Wound Healing | 2 | 2020 | 260 | 0.160 |
Why?
|
| Mentors | 1 | 2019 | 81 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 168 | 0.160 |
Why?
|
| RNA, Messenger | 8 | 2019 | 1663 | 0.160 |
Why?
|
| Caspases | 3 | 2010 | 194 | 0.160 |
Why?
|
| Caveolin 1 | 1 | 2018 | 59 | 0.160 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2012 | 74 | 0.160 |
Why?
|
| Connectin | 1 | 2017 | 14 | 0.150 |
Why?
|
| Risk Factors | 6 | 2022 | 5720 | 0.150 |
Why?
|
| Curriculum | 1 | 2021 | 575 | 0.150 |
Why?
|
| Arterial Pressure | 1 | 2017 | 46 | 0.150 |
Why?
|
| Vasodilation | 2 | 2015 | 85 | 0.150 |
Why?
|
| Decision Making | 1 | 2020 | 410 | 0.150 |
Why?
|
| Survival | 2 | 2014 | 22 | 0.140 |
Why?
|
| Cathepsins | 1 | 2016 | 37 | 0.140 |
Why?
|
| Physicians | 1 | 2020 | 324 | 0.140 |
Why?
|
| Health Promotion | 1 | 2020 | 407 | 0.140 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2017 | 139 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 467 | 0.140 |
Why?
|
| Interleukin-6 | 1 | 2017 | 330 | 0.130 |
Why?
|
| Ultrafiltration | 1 | 2015 | 35 | 0.130 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 2 | 2014 | 15 | 0.130 |
Why?
|
| RNA | 2 | 2014 | 171 | 0.130 |
Why?
|
| Dabigatran | 1 | 2015 | 35 | 0.130 |
Why?
|
| Myocarditis | 1 | 2016 | 49 | 0.130 |
Why?
|
| Postoperative Complications | 3 | 2022 | 1615 | 0.130 |
Why?
|
| Extracellular Matrix | 5 | 2019 | 493 | 0.130 |
Why?
|
| Disease Progression | 8 | 2011 | 1037 | 0.130 |
Why?
|
| Antithrombins | 1 | 2015 | 32 | 0.130 |
Why?
|
| Middle Aged | 10 | 2021 | 21119 | 0.130 |
Why?
|
| Apoptosis | 5 | 2014 | 1641 | 0.130 |
Why?
|
| Mice, Knockout | 6 | 2019 | 1692 | 0.130 |
Why?
|
| Histone Deacetylase 1 | 1 | 2015 | 32 | 0.130 |
Why?
|
| Up-Regulation | 4 | 2010 | 682 | 0.130 |
Why?
|
| Endothelins | 2 | 2006 | 57 | 0.130 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 31 | 0.130 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2014 | 12 | 0.120 |
Why?
|
| Rewarming | 2 | 2004 | 11 | 0.120 |
Why?
|
| Cardioplegic Solutions | 2 | 2004 | 15 | 0.120 |
Why?
|
| Protease Inhibitors | 2 | 2006 | 76 | 0.120 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 43 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 546 | 0.120 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2011 | 174 | 0.120 |
Why?
|
| Heart Bypass, Right | 1 | 2014 | 30 | 0.120 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 596 | 0.120 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2014 | 17 | 0.120 |
Why?
|
| Immunoblotting | 4 | 2019 | 254 | 0.120 |
Why?
|
| Gene Targeting | 1 | 2014 | 58 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Pericardium | 1 | 2014 | 97 | 0.120 |
Why?
|
| Compliance | 2 | 2015 | 26 | 0.120 |
Why?
|
| Dilatation, Pathologic | 3 | 2017 | 58 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 699 | 0.110 |
Why?
|
| Arteriovenous Malformations | 1 | 2013 | 34 | 0.110 |
Why?
|
| Fibrinolysis | 2 | 2010 | 55 | 0.110 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 173 | 0.110 |
Why?
|
| Biomarkers | 3 | 2013 | 1593 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2013 | 101 | 0.110 |
Why?
|
| Aged | 7 | 2021 | 14842 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2013 | 1753 | 0.110 |
Why?
|
| Sus scrofa | 3 | 2010 | 74 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2013 | 411 | 0.110 |
Why?
|
| Logistic Models | 2 | 2013 | 1419 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1465 | 0.100 |
Why?
|
| Coronary Circulation | 2 | 2011 | 136 | 0.100 |
Why?
|
| Recovery of Function | 3 | 2014 | 506 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7268 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2014 | 333 | 0.100 |
Why?
|
| Systole | 2 | 2010 | 149 | 0.100 |
Why?
|
| Child | 3 | 2022 | 6401 | 0.100 |
Why?
|
| Diastole | 2 | 2010 | 161 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2022 | 7028 | 0.100 |
Why?
|
| Probability | 2 | 2010 | 244 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 1533 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 371 | 0.100 |
Why?
|
| Pressure | 1 | 2012 | 252 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 2077 | 0.100 |
Why?
|
| Metalloendopeptidases | 3 | 2005 | 67 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 2 | 2010 | 384 | 0.090 |
Why?
|
| Thoracotomy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Aminocaproic Acid | 1 | 2010 | 12 | 0.090 |
Why?
|
| Heart Septal Defects | 1 | 2010 | 27 | 0.090 |
Why?
|
| Ligation | 1 | 2010 | 83 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 384 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 1046 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 83 | 0.090 |
Why?
|
| Chemokines | 1 | 2010 | 119 | 0.090 |
Why?
|
| Receptors for Activated C Kinase | 2 | 2006 | 5 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 73 | 0.090 |
Why?
|
| Reference Values | 2 | 2008 | 579 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2011 | 164 | 0.090 |
Why?
|
| Microscopy, Confocal | 4 | 2016 | 337 | 0.090 |
Why?
|
| Inflammation | 1 | 2016 | 1030 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2012 | 954 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2010 | 157 | 0.080 |
Why?
|
| Signal Transduction | 6 | 2018 | 2689 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 710 | 0.080 |
Why?
|
| Dogs | 1 | 2010 | 490 | 0.080 |
Why?
|
| Injections, Intralesional | 1 | 2008 | 25 | 0.080 |
Why?
|
| Tachycardia, Ventricular | 1 | 2010 | 153 | 0.080 |
Why?
|
| Hemostatics | 1 | 2009 | 47 | 0.080 |
Why?
|
| Microinjections | 1 | 2008 | 130 | 0.080 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 240 | 0.080 |
Why?
|
| Stress, Mechanical | 3 | 2017 | 208 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 209 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2017 | 317 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2010 | 313 | 0.080 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 320 | 0.080 |
Why?
|
| Hyperkalemia | 2 | 2004 | 21 | 0.080 |
Why?
|
| Myocardial Reperfusion | 2 | 2006 | 32 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2010 | 1040 | 0.070 |
Why?
|
| Acetylcysteine | 1 | 2010 | 296 | 0.070 |
Why?
|
| Hypertension | 1 | 2016 | 1533 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2019 | 194 | 0.070 |
Why?
|
| Age Factors | 3 | 2021 | 1860 | 0.070 |
Why?
|
| Mechanotransduction, Cellular | 2 | 2017 | 27 | 0.070 |
Why?
|
| Protein Kinase C beta | 1 | 2006 | 19 | 0.070 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2006 | 28 | 0.070 |
Why?
|
| Coronary Artery Bypass | 2 | 2005 | 218 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2004 | 235 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1549 | 0.060 |
Why?
|
| In Vitro Techniques | 3 | 2015 | 765 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2017 | 144 | 0.060 |
Why?
|
| Cicatrix | 1 | 2005 | 60 | 0.060 |
Why?
|
| Isotonic Solutions | 1 | 2004 | 25 | 0.060 |
Why?
|
| Adult | 4 | 2022 | 21379 | 0.060 |
Why?
|
| Phenotype | 3 | 2014 | 946 | 0.060 |
Why?
|
| Protein Transport | 1 | 2005 | 280 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 116 | 0.060 |
Why?
|
| Cell Movement | 2 | 2018 | 630 | 0.060 |
Why?
|
| Radio Waves | 1 | 2003 | 21 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2003 | 46 | 0.060 |
Why?
|
| Guanidines | 1 | 2003 | 32 | 0.060 |
Why?
|
| Sulfones | 1 | 2003 | 45 | 0.060 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2003 | 43 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 172 | 0.060 |
Why?
|
| Endocardium | 1 | 2003 | 101 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2004 | 93 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2010 | 334 | 0.060 |
Why?
|
| Organ Size | 1 | 2003 | 242 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 358 | 0.050 |
Why?
|
| Depression, Chemical | 1 | 2002 | 29 | 0.050 |
Why?
|
| Adrenomedullin | 1 | 2002 | 27 | 0.050 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 2002 | 10 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2017 | 1200 | 0.050 |
Why?
|
| Fibrillar Collagens | 2 | 2014 | 49 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2011 | 453 | 0.050 |
Why?
|
| Pancreatic Fistula | 1 | 2022 | 23 | 0.050 |
Why?
|
| Smad2 Protein | 2 | 2012 | 42 | 0.050 |
Why?
|
| Perioperative Period | 1 | 2021 | 24 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 67 | 0.050 |
Why?
|
| Elastin | 2 | 2015 | 116 | 0.050 |
Why?
|
| Cell Proliferation | 2 | 2017 | 1174 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 33 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2022 | 120 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4843 | 0.050 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 95 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 127 | 0.050 |
Why?
|
| Cell Survival | 1 | 2004 | 901 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2021 | 63 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2022 | 157 | 0.050 |
Why?
|
| Mastectomy | 1 | 2021 | 56 | 0.050 |
Why?
|
| Latent TGF-beta Binding Proteins | 2 | 2011 | 14 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 117 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2022 | 254 | 0.050 |
Why?
|
| Aspirin | 1 | 2022 | 295 | 0.050 |
Why?
|
| Quadriceps Muscle | 2 | 2010 | 23 | 0.040 |
Why?
|
| Punctures | 1 | 2020 | 35 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2010 | 112 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 2004 | 0.040 |
Why?
|
| Area Under Curve | 2 | 2010 | 238 | 0.040 |
Why?
|
| Calcium | 1 | 2003 | 929 | 0.040 |
Why?
|
| Reoperation | 1 | 2021 | 467 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 107 | 0.040 |
Why?
|
| Perception | 1 | 2020 | 189 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2019 | 207 | 0.040 |
Why?
|
| United States | 2 | 2022 | 7338 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 159 | 0.040 |
Why?
|
| Angiotensins | 1 | 2018 | 16 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2018 | 69 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 378 | 0.040 |
Why?
|
| Zebrafish Proteins | 1 | 2019 | 100 | 0.040 |
Why?
|
| Registries | 1 | 2022 | 730 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 281 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2019 | 158 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 87 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 503 | 0.040 |
Why?
|
| Anxiety | 1 | 2021 | 422 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2018 | 78 | 0.040 |
Why?
|
| Ethanol | 1 | 2005 | 892 | 0.040 |
Why?
|
| Zebrafish | 1 | 2019 | 187 | 0.040 |
Why?
|
| Calcium Chloride | 2 | 2010 | 38 | 0.040 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2010 | 20 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2003 | 1329 | 0.040 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 30 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2018 | 217 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 214 | 0.040 |
Why?
|
| CD11b Antigen | 1 | 2017 | 47 | 0.040 |
Why?
|
| Neurotransmitter Agents | 2 | 2012 | 102 | 0.040 |
Why?
|
| Antigens, Differentiation | 1 | 2017 | 49 | 0.040 |
Why?
|
| Heart Valves | 1 | 2019 | 171 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2009 | 191 | 0.040 |
Why?
|
| Base Sequence | 1 | 2019 | 1015 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 86 | 0.040 |
Why?
|
| Troponin I | 2 | 2010 | 34 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2017 | 38 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2017 | 101 | 0.040 |
Why?
|
| Postoperative Period | 2 | 2010 | 238 | 0.040 |
Why?
|
| Cathepsin L | 1 | 2016 | 10 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 785 | 0.040 |
Why?
|
| Cathepsin K | 1 | 2016 | 16 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2020 | 402 | 0.040 |
Why?
|
| Intracellular Space | 1 | 2016 | 42 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2017 | 230 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 94 | 0.040 |
Why?
|
| Monocytes | 1 | 2017 | 210 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 561 | 0.040 |
Why?
|
| Actins | 2 | 2010 | 249 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2021 | 657 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 627 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2022 | 2455 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1745 | 0.030 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2015 | 8 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 94 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2016 | 140 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 175 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2016 | 371 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 2014 | 60 | 0.030 |
Why?
|
| Heparin | 1 | 2015 | 205 | 0.030 |
Why?
|
| Electrophysiology | 1 | 2014 | 160 | 0.030 |
Why?
|
| Rats | 2 | 2016 | 5300 | 0.030 |
Why?
|
| Liver | 2 | 2010 | 1118 | 0.030 |
Why?
|
| Vasoconstrictor Agents | 1 | 2015 | 107 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 244 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2014 | 146 | 0.030 |
Why?
|
| Macrophages | 1 | 2017 | 647 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2016 | 331 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 200 | 0.030 |
Why?
|
| Infant | 2 | 2010 | 2891 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2798 | 0.030 |
Why?
|
| Mitral Valve | 1 | 2014 | 166 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2013 | 104 | 0.030 |
Why?
|
| Quality of Life | 1 | 2021 | 1515 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2014 | 295 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2014 | 311 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2013 | 32 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1034 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 328 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 81 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 56 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1752 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 376 | 0.030 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2012 | 7 | 0.030 |
Why?
|
| Purkinje Fibers | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2012 | 11 | 0.030 |
Why?
|
| Constriction | 1 | 2012 | 37 | 0.030 |
Why?
|
| Cell Size | 1 | 2012 | 76 | 0.030 |
Why?
|
| Connexins | 1 | 2012 | 35 | 0.030 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 168 | 0.030 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 718 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 282 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 521 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 168 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 2012 | 213 | 0.020 |
Why?
|
| Transfection | 1 | 2012 | 782 | 0.020 |
Why?
|
| Action Potentials | 1 | 2012 | 223 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 172 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 5710 | 0.020 |
Why?
|
| Microbubbles | 1 | 2010 | 8 | 0.020 |
Why?
|
| Gelatinases | 1 | 2010 | 12 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 144 | 0.020 |
Why?
|
| Enzyme Precursors | 1 | 2010 | 27 | 0.020 |
Why?
|
| Myosins | 1 | 2010 | 34 | 0.020 |
Why?
|
| Troponin | 1 | 2010 | 25 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 239 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2010 | 50 | 0.020 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 191 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 536 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 301 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1140 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 233 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2009 | 80 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2009 | 167 | 0.020 |
Why?
|
| Lac Operon | 1 | 2009 | 54 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 252 | 0.020 |
Why?
|
| Elasticity | 1 | 2009 | 103 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 689 | 0.020 |
Why?
|
| Rabbits | 1 | 2009 | 509 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 742 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 396 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1047 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2006 | 27 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 595 | 0.020 |
Why?
|
| Gene Expression | 1 | 2009 | 770 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 626 | 0.020 |
Why?
|
| Matrix Metalloproteinase 12 | 1 | 2005 | 31 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2005 | 11 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 248 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 92 | 0.020 |
Why?
|
| Endosomes | 1 | 2005 | 45 | 0.020 |
Why?
|
| Heart Septum | 1 | 2005 | 84 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2005 | 92 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2006 | 152 | 0.020 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2004 | 92 | 0.020 |
Why?
|
| Cardiotonic Agents | 1 | 2004 | 71 | 0.020 |
Why?
|
| Cell Separation | 1 | 2004 | 132 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2004 | 24 | 0.010 |
Why?
|
| Electrolytes | 1 | 2004 | 47 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 20 | 0.010 |
Why?
|
| Benzenesulfonates | 1 | 2003 | 30 | 0.010 |
Why?
|
| Heart Function Tests | 1 | 2003 | 33 | 0.010 |
Why?
|
| Biological Transport | 1 | 2003 | 210 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 191 | 0.010 |
Why?
|
| Sheep | 1 | 2003 | 128 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2003 | 137 | 0.010 |
Why?
|
| Xanthines | 1 | 2002 | 17 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2003 | 100 | 0.010 |
Why?
|
| Piperazines | 1 | 2003 | 206 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 236 | 0.010 |
Why?
|
| Length of Stay | 1 | 2004 | 780 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 3703 | 0.010 |
Why?
|